Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Osteonecrosis of the Jaw Related to Antiresorptive Therapy

      January 10, 2012
      By Jason M. Broderick
      Publication
      Article
      Oncology Nursing NewsNovember 2011
      Volume 5
      Issue 7

      Antiresorptive medicines used to reduce the loss of bone mass related to bone metastases or treatment toxicity are associated with an increased risk of ONJ.

      Kenneth E. Fleisher, DDS

      Bisphosphonates—antiresorptive medicines used to reduce the loss of bone mass related to bone metastases or treatment toxicity—are associated with an increased risk of osteonecrosis of the jaw (ONJ). At NCONN 2011, Kenneth E. Fleisher, DDS, associate professor, Department of Oral and Maxillofacial Surgery, New York University, discussed ONJ related to antiresorptive therapy.

      Definition and Incidence

      The American Association of Oral and Maxillofacial Surgeons (AAOMS) has a 3-tiered definition of bisphosphonate-related ONJ (BRONJ):

      • Current or previous bisphosphonate treatment
      • Exposed bone in the maxillofacial (jaws and face) for >8 weeks
      • No history of radiation therapy to the jaws

      Fleisher said current evidence-based research suggests ONJ is a process that involves immunologic, bacterial, and anatomic changes. While some patients may be asymptomatic, others have pain, infection, bone destruction, and/or oral dysfunction.

      The highest BRONJ rates are observed in patients with multiple myeloma and breast cancer. Additionally, the disease more commonly occurs in the lower jaw than in the upper jaw.

      Nurses Perspective

      Colleen M. O’Leary, RN, MSN, AOCNS® Otolaryngology Clinical Nurse Specialist The James Cancer Hospital The Ohio State University Medical Center, Columbus

      The use of an interdisciplinary team is imperative to managing patients with cancer who are going to receive bisphosphonate treatment. Having a dentist or oral surgeon as part of the oncology team would greatly benefit the patients assuring they have thorough dental exams and needed procedures prior to starting therapy. This would then allow the role of the nurse to include assessment, evaluation, and coordination of care of these patients.

      Excellent oral assessment is crucial to discovering early stages of ONJ. Patients with ONJ typically present with mandibular pain, purulent oral secretions, poor wound healing in the affected areas, and spontaneous intraoral tissue breakdown leading to exposure of necrotic maxillary or mandibular bone. Secondary infections may also occur (eg, actinomyces), resulting in osteomyelitis. Symptoms can range from negligible to severe, and often patients may be symptomatic for weeks to months.

      Stopping bisphosphonate therapy or using other medications has not improved outcomes. Research shows discontinuing bishphosphonate therapy can put the patient at a higher risk of further bone or skeletal related events related to their cancer. It had been hoped the nonbisphosphonate denosumab (Xgeva) would offer patients a safer option, however the incidence of ONJ with denosumab is similar to that of the bisphosphonates.

      Treatment of ONJ ranges from mild to aggressive, depending on the stage as defined by AAOMS. Nurses are critical in educating patients about treatments such as oral rinses and antibiotic use as a mild treatment. Candid discussions involving all members of the oncology team and the patient will continue to be necessary to providing the safest and most effective treatment plans.

      Source

      Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol. 2009;36(8):1835-1837.

      BRONJ mostly occurs in patients taking zoledronic acid (Zometa), pamidronate (Aredia), or a combination of both drugs. BRONJ risk is greater with intravenous (IV) bisphosphonates, which may be related to the greater potency of these drugs and/or medical comorbidities for patients with metastatic disease and multiple myeloma.

      Fleisher said that denosumab (Xgeva) has similar rates of ONJ incidence as bisphosphonates.

      Most BRONJ cases are preceded by dental extraction; however, Fleisher noted that spontaneous development can occur. Other BRONJ risk factors include poor oral health, chemotherapy, anemia, diabetes, hypertension, methotrexate use, and steroid therapy. Fleisher also said his data do not support a positive correlation between bisphosphonate treatment duration and onset of BRONJ, thus suggesting there may be other contributory factors, such as infection.

      Prevention and Diagnosis

      To reduce BRONJ risk before starting bisphosphonate treatment, patients should have dental examinations and complete all oral procedures, including tooth extractions, restorative dentistry, and periodontal treatment. Once bisphosphonate therapy begins, BRONJ assessment includes both questions and physical examination.

      Fleisher said nurses managing patients receiving bisphosphonates should ask about their dental history, including any recommendations for tooth extraction, and inquire about any recent oral symptoms, including pain, swelling, and neurological changes.

      Physical evaluation should include examination of the oral cavity, looking for exposed bone, swelling, or fistulas. If any of these symptoms appear, Fleisher said nurses should immediately refer patients to an oral and maxillofacial surgeon. Additionally, since some patients may not have exposed bone at presentation, nurses may need to advocate for diagnostic imaging.

      Treatment

      The AAOMS developed a staging system for BRONJ with accompanying treatment recommendations. Treatments range from antibiotics and antibacterial mouth rinses to surgical removal of necrotic bone.

      Exclusive Interview With Kenneth E. Fleisher, DDS

      Nurses managing patients receiving BRONJ should monitor swelling, pain, signs of infection, neurological changes, and exposed bone to evaluate whether treatment should move beyond conservative management.

      When BRONJ progresses and requires surgical intervention, the first step is conservative debridement. Fleisher said advanced imaging is also valuable at this stage. If the disease continues to progress, other techniques Fleisher uses with advanced-stage BRONJ management include tetracycline-guided debridement, perioperative intravenous antibiotic therapy, hyperbaric oxygen therapy, and cone beam CT scanning.

      While BRONJ has been treated by discontinuing bisphosphonate treatment through “drug holidays,” Fleisher said evidence is lacking for this strategy.

      Articles in this issue

      Psychosocial Considerations in Cancer Care
      Osteonecrosis of the Jaw Related to Antiresorptive Therapy
      Oncofertility: Updates on Fertility Preservation Related to Cancer Care
      Breast Cancer Treatment Update
      Clinical Management of Primary Brain Tumors
      3rd Annual NCONN Conference: Including insights from Harold P. Freeman, MD, FACS, the founder of patient navigation
      Lynch Syndrome International
      What is the best way to administer bendamustine, since some clinicians classify it as an irritant and others classify it as a vesicant?
      Assessment Comes First in Navigating Young Adults With Cancer
      Navigation: All Nurses Play a Role

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman with gray hair on a light blue background
      Photo of a man wearing scrubs in front of a blue background
      Related Content

      Graphic of myeloma cells

      Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden

      Bridget Hoyt
      June 25th 2025
      Article

      Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.


      Magazine page with Rx Road Map for Durvalumab for Non-Small Cell Lung Cancer

      Rx Road Map: Durvalumab for Non-Small Cell Lung Cancer

      Stacey Hield, BSN, RN, OCN
      June 19th 2025
      Article

      Read Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.


      Photo of two women smiling with their arms around each other, one with a headwrap

      No One Should Face Cancer Alone: The Power of Community in Cancer Care

      Marissa Fors LCSW, OSW-C, CCM
      June 18th 2025
      Article

      Ask patients, "Who's in your corner?"


      Photo of a nurse recording data on a computer and tablet

      The Evolving Role of the Oncology Nurse in Clinical Trials

      Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN
      June 14th 2025
      Article

      Oncology nurses are paramount to the treatment success of patients, especially through their work on clinical trials.


      Photo of an APP talking to and empowering a patient

      Case Study: Bridging the Gap for Patients With Metastatic CRC

      Randi Kihnel, MSN, APRN, ACCNS-AG
      June 13th 2025
      Article

      Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.


      PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

      Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

      Sylwia Zielinska, RN
      Published: May 7th 2025 | Updated: June 5th 2025
      Article

      A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

      Related Content

      Graphic of myeloma cells

      Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden

      Bridget Hoyt
      June 25th 2025
      Article

      Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.


      Magazine page with Rx Road Map for Durvalumab for Non-Small Cell Lung Cancer

      Rx Road Map: Durvalumab for Non-Small Cell Lung Cancer

      Stacey Hield, BSN, RN, OCN
      June 19th 2025
      Article

      Read Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.


      Photo of two women smiling with their arms around each other, one with a headwrap

      No One Should Face Cancer Alone: The Power of Community in Cancer Care

      Marissa Fors LCSW, OSW-C, CCM
      June 18th 2025
      Article

      Ask patients, "Who's in your corner?"


      Photo of a nurse recording data on a computer and tablet

      The Evolving Role of the Oncology Nurse in Clinical Trials

      Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN
      June 14th 2025
      Article

      Oncology nurses are paramount to the treatment success of patients, especially through their work on clinical trials.


      Photo of an APP talking to and empowering a patient

      Case Study: Bridging the Gap for Patients With Metastatic CRC

      Randi Kihnel, MSN, APRN, ACCNS-AG
      June 13th 2025
      Article

      Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.


      PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

      Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

      Sylwia Zielinska, RN
      Published: May 7th 2025 | Updated: June 5th 2025
      Article

      A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

      Latest Conference Coverage

      Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.